Delivery Order SPE2DB24D1205-SPE2DB25FCYYN
- Not listed
- The Defense Logistics Agency awarded a $13,846.97 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Vyndamax 61 mg capsule unit dose packages in quantities of 30. The contract utilizes firm fixed pricing with an ultimate completion date of August 8, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same municipality. This...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $13,846.97 for Vyndamax 61 mg capsule unit dose 30-count packages under a firm fixed price contract. The award was made on July 23, 2025, with an ultimate completion date of August 13, 2025, with performance at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded without set-aside designation and represents a routine pharmaceutical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $13,846.97 on July 28, 2025, for the supply of Vyndamax 61 mg capsule unit dose packages (30-count) with a completion deadline of August 18, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $13,846.97 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for Vyndamax 61 mg capsule unit dose 30-count packages. This is a firm fixed-price, competitively awarded contract with an ultimate completion date of August 8, 2025, and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract contains no set-aside designation, reflecting open competition among qualified vendors. This delivery...
- The Defense Logistics Agency awarded a $13,846.97 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Vyndamax 61 mg capsules (unit dose, 30-count packages) with an ultimate completion date of August 8, 2025. The contract, issued on July 18, 2025, is unclassified and carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical...
- The Defense Logistics Agency awarded a $13,846.97 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Vyndamax 61 mg capsules in unit-dose packaging (30-count). The contract, with an ultimate completion date of August 12, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This competitively...
- The Defense Logistics Agency awarded a $27,693.94 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for supply of Vyndamax 61 mg capsule unit dose packages in quantities of 30. This non-set-aside award was competitively procured and is scheduled for completion by August 12, 2025, with performance at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a discrete task order issued under AmerisourceBergen's broader...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $13,846.97 to AmerisourceBergen Drug Corp for VYNDAMAX 61 mg capsule unit dose packaging (30-count) on July 28, 2025, with completion scheduled for August 18, 2025. This competitively awarded, firm fixed price delivery order represents a child contract against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,846.97 to AmerisourceBergen Drug Corp for the supply of VYNDAMAX 61 mg capsule UD 30s, a pharmaceutical product for military healthcare needs. The award, made on July 21, 2025, with an ultimate completion date of August 11, 2025, represents a firm fixed price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, performed the contract from its Corporate...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Vyndamax 61 MG Capsule UD 30S, a pharmaceutical product, with a ceiling value of $27,693.94 and a completion date of July 7, 2025. The contract is a firm fixed-price delivery order, with no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp, a for-profit organization based in...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCYYNDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Vyndamax 61 mg capsule unit dose packages (30-count). This order, valued at $13,846.97 with a firm fixed price structure, represents a non-competitive, non-set-aside procurement issued under a delivery order contract type and is scheduled for completion by August 18, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and primary distribution operations. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. As a prime vendor in the DLA's pharmaceutical supply chain, AmerisourceBergen supplies a comprehensive range of medications and medical commodities to support military healthcare programs globally, including support for the Defense Health Agency and U.S. Coast Guard. The company's contract portfolio reflects its established capability to provide both brand-name and generic pharmaceuticals across multiple therapeutic domains under competitive federal procurement requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.8k | 7/28/25 |